Palo Santo — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management.
AI & Machine LearningBiotechDigital HealthHealthtechNew York City, US
Jonathan Sporn(Founder)inAndrew Kruegel(Founder)inDalibor Sames(Founder)inJONATHAN SPORN(Founder)inAndrew Kruegel, Ph.D.(Executive Officer)Jonathan Sporn, M.D.(President and Chief Executive Officer)in
Co-investorsAera VCFrontera Technology VenturesFrontier Path VCJames Beshara FundJLSMagnetic Ventures+9 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.